Geert Mudde

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Immunotherapy Research. Top assignees: F-Star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h, S-Target Therapeutics Gmbh, Baxalta Gmbh. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Geert Mudde. Retrieved from https://idiyas.com/inventor/geert-mudde

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 93.3

CIPO Patents = 3

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Vienna, AT (2017)
Breitenfurt bei Wien, AT (2019)
Breitenfurt, AT (2010 - 2021)

Company Filing History:

5 out of 10

F-Star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h

patents

3 out of 3

S-Target Therapeutics Gmbh

Greenovation Biotech Gmbh

patents

5. 2 out of 2

Meridian Biopharmaceuticals Gmbh

Baxter International Inc.

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

Areas of Expertise:

Her2/neu

Immunogenic Composition

Bispecific Molecules

Cytotoxic Immunoglobulin

T Cell Epitope

Immunoregulatory Vaccine

Antibody

Gastrin Peptide

Binding Agents

CHO-MIF

MIF Antibodies

Lewis Y Tumors

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11154599 - Her2/neu immunogenic composition (2021-10-26),

2. 11090381 - Coiled-coil connector (2021-08-17),

3. 10434170 - Immunoregulatory vaccine (2019-10-08),

4. 10328134 - Gastrin peptide immunogenic composition (2019-06-25),

5. 10189905 - Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies (2019-01-29),

6. 10125197 - Cytotoxic immunoglobulin (2018-11-13),

7. 9651559 - Display of binding agents (2017-05-16),

8. 9636415 - Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies (2017-05-02),

9. 9465037 - Characterization of CHO-MIF gene and protein, and use thereof (2016-10-11),

10. 9255149 - Cytotoxic immunoglobulin (2016-02-09),

11. 8921279 - Display of binding agents (2014-12-30),

12. 8859738 - Cytotoxic immunoglobulin (2014-10-14),

13. 8668909 - Anti MIF antibodies (2014-03-11),

14. 8323650 - Method of treating lewis Y-expressing tumors (2012-12-04),

15. 7759464 - N-glycosylated antibody (2010-07-20),

Title: Geert Mudde: Innovator in Immunogenic Compositions

Introduction

Geert Mudde is a prominent inventor based in Breitenfurt, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of immunogenic compositions and connectors for protein structures. With a total of 15 patents to his name, Mudde's work has the potential to impact medical treatments significantly.

Latest Patents

One of Mudde's latest patents is the Her2/neu immunogenic composition. This invention provides an immunogenic composition that includes a directed adjuvant with an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix. Additionally, it features an immunogen comprising an extracellular Her2/neu domain linked to a second peptidic alpha-helix coiled to the first alpha-helix. This invention also includes a kit for producing the immunogenic composition, a vaccine containing it, and its medical applications for treating Her2/neu positive tumor diseases.

Another notable patent is the coiled-coil connector. This invention describes a connector of a helical coiled coil-type structure that connects two molecules. The first molecule consists of a peptidic first alpha-helix, while the second molecule comprises a peptidic second alpha-helix coiled to the first. This innovative connector allows for the connection of two polypeptide chains in a multimeric protein.

Career Highlights

Throughout his career, Geert Mudde has worked with several notable companies, including F-star Biotechnologische Forschungs- und Entwicklungsges.m.b.h and S-Target Therapeutics GmbH. His work in these organizations has contributed to advancements in biotechnological research and development.

Collaborations

Mudde has collaborated with esteemed colleagues such as Gottfried Himmler and Gerda Redl. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Geert Mudde's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments and immunogenic research.

Profile summary based on public USPTO records.